KOD Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals has a net margin of -- compared to Kodiak Sciences's net margin of -55.29%. Kodiak Sciences's return on equity of -- beat Apellis Pharmaceuticals's return on equity of -96.34%.

Kodiak Sciences has a consensus price target of $7.25, signalling upside risk potential of 39.69%. On the other hand Apellis Pharmaceuticals has an analysts' consensus of $35.45 which suggests that it could grow by 76.9%. Given that Apellis Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Apellis Pharmaceuticals is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.276, which suggesting that the stock is 127.607% more volatile than S&P 500. In comparison Apellis Pharmaceuticals has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.72%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Apellis Pharmaceuticals pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Apellis Pharmaceuticals quarterly revenues of $166.8M. Kodiak Sciences's net income of -$57.5M is higher than Apellis Pharmaceuticals's net income of -$92.2M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Apellis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 3.22x for Apellis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Design Therapeutics has a net margin of -- compared to Kodiak Sciences's net margin of --. Kodiak Sciences's return on equity of -- beat Design Therapeutics's return on equity of --.

Kodiak Sciences has a consensus price target of $7.25, signalling upside risk potential of 39.69%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 82.42%. Given that Design Therapeutics has higher upside potential than Kodiak Sciences, analysts believe Design Therapeutics is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.276, which suggesting that the stock is 127.607% more volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Design Therapeutics quarterly revenues of --. Kodiak Sciences's net income of -$57.5M is lower than Design Therapeutics's net income of -$17.7M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Kodiak Sciences's net margin of -49.65%. Kodiak Sciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Kodiak Sciences has a consensus price target of $7.25, signalling upside risk potential of 39.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Kodiak Sciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Kodiak Sciences is more attractive than NovaBay Pharmaceuticals.

Kodiak Sciences has a beta of 2.276, which suggesting that the stock is 127.607% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Kodiak Sciences's net income of -$57.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Kodiak Sciences's net margin of --. Kodiak Sciences's return on equity of -- beat Theriva Biologics's return on equity of --.

Kodiak Sciences has a consensus price target of $7.25, signalling upside risk potential of 39.69%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than Kodiak Sciences, analysts believe Theriva Biologics is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.276, which suggesting that the stock is 127.607% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Kodiak Sciences's net income of -$57.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.